Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding Aligos Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 34 | 1 | 35 | +2 |
| Shares | 1.62M | 1.10K | 3.30M | +1.68M (+103.7%) |
| Value | $64.5M | $44.0K | $27.1M | −$37.4M (−58.0%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alyeska Investment Group, L.P. | 412,000 | $3.40M | 0.01% |
| Woodline Partners LP | 315,383 | $2.60M | 0.02% |
| Heights Capital Management, Inc | 241,500 | $1.99M | 0.95% |
| Hudson Bay Capital Management LP | 241,500 | $1.88M | 0.01% |
| Sio Capital Management, LLC | 180,720 | $1.49M | 0.45% |
| Tang Capital Management LLC | 141,131 | $1.16M | 0.06% |
| Readystate Asset Management LP | 45,400 | $374.6K | 0.02% |
| Susquehanna International Group, LLP | 40,612 | $335.0K | 0.00% |
| Quest Partners LLC | 15,760 | $130.0K | 0.01% |
| Dimensional Fund Advisors LP | 11,216 | $92.5K | 0.00% |
| Two Sigma Investments, LP | 11,050 | $91.2K | 0.00% |
Sold out (9)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Ikarian Capital, LLC | 64,300 | $2.56M |
| UBS Oconnor LLC | 40,096 | $1.60M |
| Avantax Advisory Services, Inc. | 30,570 | $1.22M |
| Drive Wealth Management, LLC | 23,000 | $916.3K |
| Boothbay Fund Management, LLC | 18,543 | $738.8K |
| State Street Corp | 9,582 | $381.7K |
| Northern Trust Corp | 5,157 | $205.5K |
| Spire Wealth Management | 200 | $7.97K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 80 | $3.19K |
Not filed for Q1 2025 yet (1)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| AlphaMark Advisors, LLC | 1,100 | $44.0K |